New Study Shows Sputnik V Has 98% Efficacy In COVID-related Mortality

A comparative study of five vaccines in EU member Hungary on 3.7 million people shows Sputnik V has 85.7% efficacy against infection

By Saurabh Kumar | Nov 26, 2021
Unsplash

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur Asia Pacific, an international franchise of Entrepreneur Media.

A unique independent nationwide observational study in EU member state Hungary estimating and directly comparing efficacy of five vaccines against COVID has demonstrated that the Russian Sputnik V vaccine has the highest (98%) efficacy in preventing COVID-related mortality and 85.7% efficacy against coronavirus infection leading alongside the vaccine by Moderna.

The study based on the real world data from 3.7 million vaccinated individuals in Hungary.

Hungary was the first country in EU to authorize Sputnik V.

Between 22 January 2021 and 10 June 2021, residents of Hungary received two doses of Sputnik V, Moderna, Pfizer-BioNTech, Sinopharm or AstraZeneca vaccines as part of the national vaccination program. The Russian vaccine proved the best in protection against COVID related mortality and leads alongside the vaccine by Moderna in efficacy rate against COVID infection based on analysis of data from 820,000 individuals vaccinated with Sputnik V (see the chart below). The study has also demonstrated Sputnik V is 100 per cent effective against COVID related deaths in individuals aged 16–44 years.

.

A unique independent nationwide observational study in EU member state Hungary estimating and directly comparing efficacy of five vaccines against COVID has demonstrated that the Russian Sputnik V vaccine has the highest (98%) efficacy in preventing COVID-related mortality and 85.7% efficacy against coronavirus infection leading alongside the vaccine by Moderna.

The study based on the real world data from 3.7 million vaccinated individuals in Hungary.

Hungary was the first country in EU to authorize Sputnik V.

Between 22 January 2021 and 10 June 2021, residents of Hungary received two doses of Sputnik V, Moderna, Pfizer-BioNTech, Sinopharm or AstraZeneca vaccines as part of the national vaccination program. The Russian vaccine proved the best in protection against COVID related mortality and leads alongside the vaccine by Moderna in efficacy rate against COVID infection based on analysis of data from 820,000 individuals vaccinated with Sputnik V (see the chart below). The study has also demonstrated Sputnik V is 100 per cent effective against COVID related deaths in individuals aged 16–44 years.

.

Related Content

Business News

Fortude Further Strengthens Microsoft Cloud Capabilities with Azure Infrastructure Solutions Designation

Fortude has earned the Microsoft Azure Infrastructure Solutions designation, expanding its Microsoft cloud credentials and capabilities in enterprise cloud transformation. The designation, awarded by Microsoft, recognizes partners that demonstrate experience in designing, deploying, and managing Azure infrastructure aligned with enterprise requirements. The latest recognition adds to Fortude’s existing Microsoft credentials, including the Analytics on Microsoft […]
Business News

Dmitry Shubov Consulting Advises Southeast Asian Startups On New Philippine Supreme Court Electronic Notarization Standards

Dmitry Shubov Consulting announced that new electronic notarization rules issued by the Philippine Supreme Court will affect Southeast Asian startups preparing documents for U.S. transactions. The Court’s A.M. No. 24-10-14-SC establishes a regulatory framework for electronic notarization in the Philippines. The rules recognize accredited in-person Electronic Notarization Facilities (ENFs), Remote Electronic Notarization Providers (ENPs) using […]
Business News

WRISE Launches Client Service Center in Taiwan

Singapore-headquartered multi-family office WRISE Group has expanded its presence in Asia with the launch of a new client service center in Taipei, Taiwan. The center will offer client advisory and consultation services, alongside family wealth-focused educational and engagement initiatives designed to foster long-term perspectives and encourage next-generation dialogue. The Taipei center will be led by […]
Business News

Bank of Singapore Hires Alternative Investments Expert to Strengthen UHNW Solutions

Bank of Singapore, the private banking division of Oversea‑Chinese Banking Corporation, has appointed Bernard Heng as Head of Customised Solutions, effective 2 March 2026. The move is intended to bolster the bank’s capabilities in bespoke investment and alternative product solutions for ultra-high-net-worth (UHNW) clients. In his new role, Heng will report to Lim Leong Guan, […]